vitreous opacities

Macular Edema, Autosomal Dominant Cystoid

Clinical Characteristics
Ocular Features: 

Only a few families have been reported.  The macular edema can be traced to retinal capillary leakage throughout the posterior pole as revealed by fluorescein angiography.  Scattered exudates and nerve fiber layer hemorrhages are sometimes seen.  Hyperopia and strabismus are often present as well.  Veils, strands, and white punctate deposits in the vitreous have been described.  Wrinkling of the internal limiting membrane may be present.  The ERG is normal except for elevated rod dark adaptation thresholds.  Light/dark ratios are abnormal on EOG testing and mild dyschromatopsia can be demonstrated.  Patients usually notice problems with their visual acuity in the second decade of life and it can drop to 20/200 at this time with progression to 2/120 - 2/200 in older individuals.  In later stages of the disease a central zone of beaten bronze macular atrophy can be seen.  Surrounding this central atrophy is often an area with pigmentary changes resembling retinitis pigmentosa which can extend into the periphery.

This would seem to be a unique disorder in spite of some similarities to retinitis pigmentosa in which macular cysts are often seen.  The clinical course is distinctly different and the presence of vitreous deposits and hyperopia also can be used as arguments for its separateness.  Molecular DNA evidence showing lack of allelism (Vida infra) is, of course the strongest evidence.

Systemic Features: 

No systemic abnormalities have been reported.

Genetics

This autosomal dominant form of progressive macular dystrophy is linked to a locus at 7p21-p15.  The mutation is close to the RP9 locus causing one type of retinitis pigmentosa but linkage analysis shows the two disorders to be non-allelic.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

No specific treatment is available for the macular disease but low vision aids are likely useful, at least early in the disease.

References
Article Title: 

Cerebrotendinous Xanthomatosis

Clinical Characteristics
Ocular Features: 

Juvenile cataracts are the primary ocular feature of this disorder and are found in virtually all patients.  These often cause the first symptoms and become evident in the first decade and almost always by the third decade of life.  Lens opacification may require extraction at that time and aspirated lens material may contain lipid-containing vacuoles.  However, some cataracts may not be diagnosed until the 5th or 6th decades after the onset of neurological symptoms, usually because the opacities are located in the peripheral cortex and do not cause visual symptoms. 

Optic atrophy occurs in nearly half of affected individuals.  Yellowish flakes resembling cholesterol crystals can sometimes be seen in the vitreous. The fundus may have scattered hard exudates and cholesterol-like deposits along the vascular arcades and arterioles show evidence of atherosclerosis.  RPE window defects are common.

Systemic Features: 

CTX has serious systemic neurologic signs and symptoms resulting from a deficiency of a mitochondrial enzyme, sterol 27-hydroxylase.  The result is reduced bile acid synthesis and increased levels of cholestanol in plasma, tissues, and CSF.  This results in a characteristic phenotype of tendon xanthomas, and neurological dysfunction including mental regression or illness, cerebellar ataxia, peripheral neuropathy, seizures, and pyramidal signs to various degrees.  Neonatal jaundice and diarrhea are common.

Genetics

This autosomal recessive disorder results from a mutation in the CYP27A1 gene (2q33-qter) encoding sterol 27-hydroxylase.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

This is a treatable disorder in which administration of chenodeoxycholic acid (CDCA) is beneficial.  This compound is virtually absent from bile in people with CTX.  Exogenous administration reduces high levels of cholesterol and cholestanol in the CSF, tissues, and plasma with improvement in mental function and signs of peripheral neuropathy and cerebellar dysfunction.  It is frequently given in combination with other HMG-CoA inhibitors such as pravastatin.  Early diagnosis and treatment are important.

References
Article Title: 
Subscribe to RSS - vitreous opacities